Bulletin
Investor Alert

AbbVie Inc.

NYSE: ABBV

GO

Set Alerts

Find a Broker

Join TD Ameritrade

Market Index

Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
AbbVie Inc.

After Hours

ABBV
/quotes/zigman/13067932/composite

$

61.62

Change

+0.03 +0.05%

Volume

Volume 1.40m

Nov 29, 2016, 7:13 p.m.

Quotes are delayed by 20 min

/quotes/zigman/13067932/composite

Today's close

$ 59.46

$ 61.59

Change

+2.13 +3.58%

Day low

Day high

$59.52

$62.10

Open
Open: 59.70

52 week low

52 week high

$50.71

$68.12

Open

Market cap

$96.63B

Average volume

7.38M

P/E ratio

16.65

Rev. per Employee

$901,500

EPS

3.70

Dividend

0.64

Div yield

4.16%

Ex dividend date

1/11/17

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/abbv

MarketWatch News on ABBV

  1. AbbVie downgraded to neutral from buy at Citigroup

    11:41 a.m. Today

    - Tomi Kilgore

  3. 20 stocks that have been ‘so bad that they’re good’

    7:05 a.m. Nov. 7, 2016

    - Philip van Doorn

  5. Gilead sales of Hepatitis C drugs slump

    5:19 p.m. Nov. 1, 2016

    - MarketWatch.com

  6. Drug stocks bounce even as pricing problems spread

    2:33 p.m. Oct. 31, 2016

    - Tomi Kilgore

  7. AbbVie stock price target cut to $60 from $70 at Credit Suisse

    9:54 a.m. Oct. 31, 2016

    - Tomi Kilgore

  8. AbbVie downgraded to neutral from outperform at Credit Suisse

    9:54 a.m. Oct. 31, 2016

    - Tomi Kilgore

  9. AbbVie tops profit views, but Humira sales miss

    11:45 a.m. Oct. 28, 2016

    - MarketWatch.com

  12. AbbVie's stock slumps 2.9% in premarket trade after Q3 results

    7:52 a.m. Oct. 28, 2016

    - Tomi Kilgore

  13. AbbVie Q3 Humira revenue up 2.4% to $4.06 bln; FactSet consensus $4.17 bln

    7:50 a.m. Oct. 28, 2016

    - Tomi Kilgore

  14. AbbVie raises 2016 adj. EPS outlook to $4.80-$4.82 from $4.73-$4.83

    7:49 a.m. Oct. 28, 2016

    - Tomi Kilgore

  15. AbbVie raises quarterly dividend to 64 cents a share from 57 cents a share

    7:48 a.m. Oct. 28, 2016

    - Tomi Kilgore

  16. AbbVie Q3 revenue $6.43 bln vs. $5.94 bln; FactSet consensus $6.56 bln

    7:47 a.m. Oct. 28, 2016

    - Tomi Kilgore

  17. AbbVie Q3 adj. EPS $1.21; FactSet consensus $1.20

    7:47 a.m. Oct. 28, 2016

    - Tomi Kilgore

  18. AbbVie Q3 EPS 97 cents vs. 74 cents a year ago

    7:47 a.m. Oct. 28, 2016

    - Tomi Kilgore

  19. Index funds can be inferior to active funds in two crucial ways

    4:07 p.m. Oct. 24, 2016

    - Philip van Doorn

  20. AbbVie started at market perform with $70 stock price target at Leerink Partners

    7:45 a.m. Oct. 18, 2016

    - Tomi Kilgore

  21. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/abbv

Other News on ABBV

  1. U.S. Stocks Edge Higher

    4:09 p.m. Today

    - The Wall Street Journal Interactive Edition

  2. Testing of Treatment for Cystic Fibrosis Patients Begins

    3:19 p.m. Today

    - GuruFocus.com

  3. AbbVie’s Financial Guidance for 2017

    2:00 p.m. Today

    - MarketRealist.com

  4. New Indications May Be Big Opportunity for AbbVie’s Imbruvica

    2:00 p.m. Today

    - MarketRealist.com

  5. Next-Generation Hepatitis C Therapy May Be AbbVie’s Growth Driver

    2:00 p.m. Today

    - MarketRealist.com

  6. Analyzing Allergan’s Growth Pharma Plans

    1:26 p.m. Today

    - MarketRealist.com

  7. Allergan’s News: Recent Acquisitions and Divestments

    1:26 p.m. Today

    - MarketRealist.com

  8. Healthcare Stocks Help Nasdaq Reach New Heights

    12:31 p.m. Today

    - TheStreet.com

  12. Amgen: Enbrel Is Undervalued

    7:45 p.m. Nov. 28, 2016

    - Seeking Alpha

  13. Holiday Shopping Sale: Amgen

    1:47 p.m. Nov. 28, 2016

    - Seeking Alpha

  14. 3 Top Drug Stocks for Your Retirement Portfolio

    10:55 a.m. Nov. 28, 2016

    - Motley Fool

  15. Elagolix May Become a Leading Uterine Fibroids Drug

    1:10 a.m. Nov. 26, 2016

    - MarketRealist.com

  16. AbbVie’s Imbruvica Expected to Become a Leading Oncology Drug

    1:10 a.m. Nov. 26, 2016

    - MarketRealist.com

  17. Elagolix May Become a Strong Growth Driver for AbbVie

    1:10 a.m. Nov. 26, 2016

    - MarketRealist.com

  20. The US is Gilead Sciences’s Major Market

    12:44 a.m. Nov. 26, 2016

    - MarketRealist.com

  21. Loading more headlines...
/news/pressrelease/company/us/abbv

Press Releases on ABBV

  2. Global Endometriosis Industry

    5:45 p.m. Nov. 23, 2016

    - PR Newswire - PRF

  4. Biotech-Cannabis Stocks Move on Election, State Ballots

    8:00 a.m. Nov. 15, 2016

    - PR Newswire - PRF

  10. AbbVie Announces European Fixed Income Investor Meetings

    8:30 a.m. Nov. 2, 2016

    - PR Newswire - PRF

  14. AbbVie Increases Quarterly Dividend by 12.3 Percent

    9:37 a.m. Oct. 28, 2016

    - PR Newswire - PRF

  15. AbbVie Reports Third-Quarter 2016 Financial Results

    7:43 a.m. Oct. 28, 2016

    - PR Newswire - PRF

  19. AbbVie to Host Third-Quarter Earnings Conference Call

    8:00 a.m. Oct. 10, 2016

    - PR Newswire - PRF

  21. Loading more headlines...

Rates »

Mortgage Equity Savings Auto CREDIT CARDS
5 yr CD
1.2%
2 yr CD
0.8%
1 yr CD
0.6%
MMA $10K+
0.3%
MMA $50K+
0.4%
MMA Savings
0.3%
MMA Savings Jumbo
0.4%

National averages from Bankrate.com

You Don’t Need Another Credit Card, You Need A Better One.
Avg. APR Last Week 6 Months
Low Interest 12.00% 12.00% 11.96%
Business 13.12% 13.12% 13.12%
Student 13.42% 13.42% 13.42%
Balance Transfer 14.41% 14.41% 14.39%
Airline 15.13% 15.13% 15.17%
Reward 15.24% 15.24% 15.30%
Cash Back 15.33% 15.33% 15.30%
Instant Approval 17.86% 17.86% 18.04%
Bad Credit 22.86% 22.86% 22.56%
Source:CreditCards.com
Trending Tickers
  • /quotes/zigman/78102759/composite NTNX+2.25%
  • /quotes/zigman/413712/composite USO-3.64%
  • /quotes/zigman/4194817/composite SCO+6.99%
  • /quotes/zigman/14634168/composite TXMD-15.46%
  • /quotes/zigman/9588578/composite SPLK-0.07%
X
Powered by StockTwits
Link to MarketWatch's Slice.